Navigation Links
Multiple disease-related research gets green light from the NIH
Date:9/16/2008

Saranac Lake, N.Y. - Stephen Smiley, Ph.D., a member of the scientific faculty at the Trudeau Institute, whose research could lead to new treatments for several common diseases, has been awarded a research grant from the National Institutes of Health (NIH) for nearly $2 million.

Dr. Smiley and members of his laboratory are working to develop treatments for a number of diseases where an abnormal activation of blood coagulation pathways causes damage to the body. The diseases include multiple sclerosis (MS), rheumatoid arthritis, transplant rejection and sepsis, a leading cause of hospital deaths. In particular, Dr. Smiley's laboratory is studying fibrin, a blood-clotting protein that frequently accumulates at high levels in diseased tissues. These high levels of fibrin are thought to clog blood vessels and cause inflammation, thereby starving tissues of oxygen and increasing the severity of disease.

With prior funding from the NIH, Dr. Smiley's laboratory collaborated with Trudeau colleague Larry Johnson to demonstrate that, despite the risks it poses, fibrin also performs critical protective functions during immune responses.

The researchers showed that fibrin deposition is essential for survival during certain infections. Specifically, they found that fibrin staunches bleeding caused by protective immune cells as they rid the body of infected cells. In addition to protecting against this collateral damage caused by the immune system itself, Drs. Smiley and Johnson also discovered that fibrin suppresses the growth of some unhealthy bacteria.

These prior studies led the scientists to hypothesize that the human body needs to maintain a careful balance of proper fibrin levels during immune responses: "Some fibrin deposition is essential for good health, while too much can be dangerous and harmful," explained Dr. Smiley.

"I'm very pleased the NIH is continuing to support Dr. Smiley's research," said David L. Woodland, Ph.D., president and director of the Trudeau Institute. "Cutting-edge research of this caliber has the potential to lead to improved treatments for people afflicted with a number of debilitating diseases, in addition to those who suffer transplant rejections."

Dr. Smiley believes that prior attempts to treat patients suffering from sepsis by removing fibrin failed because those treatments most likely removed both unhealthy and healthy fibrin. With this infusion of research funds, Dr. Smiley's laboratory will now seek to identify what exactly tips the balance between healthy and unhealthy levels of fibrin. They recently discovered that cytokines, soluble signaling molecules within the immune system, play a primary role in regulating this balance. Now they are using a variety of models and methods to delineate precisely how cytokines regulate fibrin levels.

The NIH funds will support Dr. Smiley's research efforts over a four-year period.


'/>"/>

Contact: Brian Turner
brianturner@trudeauinstitute.org
518-891-3080
Trudeau Institute
Source:Eurekalert  

Related biology news :

1. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
2. Nicotinic receptors may be important targets for treatment of multiple addictions
3. Emphasis on conifer forests places multiple species at risk
4. For honey bee queens, multiple mating makes a difference
5. Israeli scientists identify: Genes that affect responses of multiple sclerosis patients to copaxone
6. New magnetic separation technique might detect multiple pathogens at once
7. The power of multiples: Connecting wind farms can make a more reliable - and cheaper - power source
8. Multiple species of bacteria may cause trachoma: Implications for treatment
9. Multiple resource management is focus of new technical report
10. Potential new target for multiple sclerosis therapy
11. Fast AFM probes measure multiple properties of biomolecules or materials simultaneously
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Multiple disease-related research gets green light from the NIH
(Date:1/11/2017)... 11, 2017  Michael Johnson, co-founder of Visikol Inc. a company ... has been named to the elite "Forbes 30 Under 30" list ... 600 people in 20 fields nationwide to be recognized as a ... applicants were selected. ... He is currently a PhD candidate at Rutgers University. ...
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... sensor technology, today announced the launch of two ... systems, the highly-accurate biometric sensor modules that incorporate ... technology, experience and expertise. The two new designs ... specifically for hearables, and Benchmark BW2.0, a 2-LED ...
(Date:12/20/2016)... N.C. and GENEVA, Dec, 20, 2016 /PRNewswire/ ... biometric data sensor technology, and STMicroelectronics ... the spectrum of electronics applications, announced today the ... development kit for biometric wearables that includes ST,s ... with Valencell,s Benchmark™ biometric sensor system. ...
Breaking Biology News(10 mins):
(Date:1/12/2017)... DC , January 12, 2017 ... up the world,s biggest facility for producing mycorrhizae. The ... the nutrient tapping potential of mycorrhizae and developed a ... ... (Logo: http://mma.prnewswire.com/media/456932/PRNE_TERI_Logo.jpg) The TERI facility ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... enhanced the platform to accommodate increasingly complex and sophisticated deployments, resulting in ... more. In addition to these improvements, the latest release brings enhanced data ...
(Date:1/11/2017)... ... 11, 2017 , ... Photonics industry and STEM advocates associated ... the U.S. Congress and President Obama for their recognition of the importance of ... Innovation and Competitiveness Act (AICA). , The language of the act (S. 3084) ...
(Date:1/11/2017)... ... January 11, 2017 , ... Microbial genomics leader uBiome, ... Its most recent microbiome impact grant award has been made to Dr. Eon ... long-term use of oral antibiotics, prescribed for skin conditions, on the gut microbiome. ...
Breaking Biology Technology: